We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ranbaxy Dealt Blow in Bid to Reclaim Generic Nexium, Valcyte Approvals
Ranbaxy Dealt Blow in Bid to Reclaim Generic Nexium, Valcyte Approvals
A federal judge has sided with the FDA in its decision to strip Ranbaxy of generic approval and first-filer rights to Nexium and Valcyte, meaning company’s efforts to control the generic market for the two drugs could be over unless it appeals.